GILD logo

Gilead Sciences, Inc.

GILD
Healthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18
Next Earnings Report
Feb 9, 2027
EPS est. $1.39 · Revenue est. $8.28B
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Aug 6, 2026 (S-3ASR). Possible dilution.

Upcoming Data Readouts (57)

Dec 2026
Est. completion
P2Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Dec 2026
Est. completion
P1Localized Muscle Invasive Bladder Urothelial Carcinoma
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Dec 2026
Est. completion
P2Biliary Tract Carcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Dec 2026
Est. completion
P1Gastrointestinal Cancer
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Dec 2026
Est. completion
P1Solid Tumors
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Jan 2027
Est. completion
P2Ulcerative Colitis
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Jan 2027
Est. completion
P2Stage III Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Feb 2027
Est. completion
P1P2Breast Cancer
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Feb 2027
Est. completion
P3Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Feb 2027
Est. completion
P1P2Advanced Breast Cancer
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Mar 2027
Est. completion
Metastatic Breast Cancer
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311n=42,000
Mar 2027
Est. completion
P2Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Mar 2027
Est. completion
P2Non-small Cell Lung Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Mar 2027
Est. completion
P3HER2-negative Breast Cancer
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
Mar 2027
Est. completion
P4HIV
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
May 2027
Est. completion
P2Thymoma
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
May 2027
Est. completion
P2Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
Jun 2027
Est. completion
P3Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Jun 2027
Est. completion
P4HIV -1 Infection
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Jul 2027
Est. completion
Liver Cirrhosis
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors

Awaiting Results (15)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P1
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
NCT05457010
Oct 2026
P3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
NCT05552001
Oct 2026
P1
Study of GS-4528 in Adults With Solid Tumors
NCT05840224
Sep 2026
P4
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
NCT05140941
Sep 2026
P2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150
Aug 2026
P4
Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06374758
Apr 2026
P3
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299
Oct 2025
P3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808
Jun 2025
P2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530
Mar 2025
P2P3
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
NCT02881320

SEC Filings (78)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13GPassive 5%+ stakeDocumentIndex
Nov 6, 202613F-HRInstitutional holdings reportDocumentIndex
Oct 30, 202610-QQuarterly reportDocumentIndex
Oct 29, 20268-KMaterial eventDocumentIndex
Aug 26, 2026N-PXDocumentIndex
Aug 7, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 6, 2026S-3ASRShelf registrationDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 4, 20268-KMaterial eventDocumentIndex
Aug 3, 202613F-HRInstitutional holdings reportDocumentIndex
May 27, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 20, 20268-KMaterial eventDocumentIndex
May 18, 2026424B5Offering prospectusDocumentIndex
May 14, 2026FWPDocumentIndex
May 14, 2026424B5Offering prospectusDocumentIndex
May 8, 202613F-HRInstitutional holdings reportDocumentIndex
May 7, 2026S-8Employee stock planDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 29, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 28, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Apr 28, 20268-KMaterial eventDocumentIndex
Apr 28, 2026SC TO-T/ATender offerDocumentIndex
Apr 17, 2026SC TO-T/ATender offerDocumentIndex
Apr 1, 2026SC TO-T/ATender offerDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 20, 2026ARSAnnual report to holdersDocumentIndex
Mar 20, 2026DEFA14AProxy / shareholder voteDocumentIndex
Mar 20, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 6, 2026SC TO-TTender offerDocumentIndex
Feb 24, 202610-KAnnual reportDocumentIndex
Feb 23, 2026SC TO-CTender offerDocumentIndex
Feb 23, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Feb 23, 2026SC TO-CTender offerDocumentIndex
Feb 23, 20268-KMaterial eventDocumentIndex
Feb 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 12, 202613F-HRInstitutional holdings reportDocumentIndex
Feb 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 10, 20268-KMaterial eventDocumentIndex